Ali McBride, PharmD
Real-world data presented at the 2017 Gastrointestinal Cancers Symposium demonstrated that significantly higher costs were associated with FOLFIRINOX (5-fluorouracil, leucovorin, irinotecan, oxaliplatin) as frontline therapy compared with the combination of nab-paclitaxel and gemcitabine in patients with metastatic pancreatic cancer (MPC).
McBride A, Bonafede M, Cai Q, et al. Health care costs and treatment patterns among metastatic pancreatic cancer (MPC) patients (pts) initiating first-line (1L) on nab-paclitaxel/gemcitabine (nab-P+G) or FOLFIRINOX (FFX). Presented at: 2017 Gastrointestinal Cancers Symposium; January 19-21, 2017; San Francisco, CA. Abstract 415.
... to read the full story